Trihex

Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio

Retrieved on: 
Thursday, August 25, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Cosmetics, Clinical Trials, Retail, COVID-19, Safety, IGA, Nemolizumab, Significance, Tretinoin, Science, Filler (animal food), International, Adult, Congress, Hyaluronic acid, Dermatology, Forte, Patient, City, Sale, Importance, Prurigo nodularis, Benzoyl peroxide, EBITDA, Skin, Projection, Aesthetics, Republican Political Alliance for Integrity and Reform, Acquisition, Growth, Galderma, Neuromodulation, Development, NYSE, Trihex, Heart, III, Perkinsus marinus, Environment, Pharmaceutical industry, Renewable energy

With its continued commitment to innovation and broad channel exposure, Galderma is well positioned to capitalize on this growing consumer demand.

Key Points: 
  • With its continued commitment to innovation and broad channel exposure, Galderma is well positioned to capitalize on this growing consumer demand.
  • In Injectable Aesthetics, Galderma continued to grow strongly in an environment of resilient consumer demand.
  • In Dermo-cosmetics, Galderma continued to outperform the market, with double-digit growth in eight out of the top 10 markets for the product category.
  • In Therapeutic Dermatology, Galderma navigated the anticipated annualization effect of the U.S. loss of exclusivity of Epiduo Forte and Soolantra with new launches.

Galderma Successfully Completes Acquisition of ALASTIN Skincare®

Retrieved on: 
Wednesday, January 5, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Latham & Watkins, Dermatology, Acquisition, Bajaj Consumer Care, Growth, Skin, Company, Patient, Trihex, Ropes & Gray, William Blair & Company, Partnership, LLC, Peptide, Collection, Pharmaceutical industry, Fine chemical, Aesthetics

Galderma, the worlds largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products.

Key Points: 
  • Galderma, the worlds largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products.
  • I am so happy to officially welcome the ALASTIN team to Galderma.
  • Galderma has consistently delivered strong results and remains at the forefront of the rapidly expanding global skincare market.
  • Ropes & Gray LLP acted as legal advisor to Galderma, and Latham & Watkins LLP acted as legal advisor to ALASTIN.

Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients

Retrieved on: 
Monday, November 29, 2021
Other Consumer, Research, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Science, Patient, William Blair & Company, Skin, Peptide, Industry, Acquisition, INC, Company, CAGR, Partnership, Dermatology, Bajaj Consumer Care, Trihex, Physician, Research, LLC, Collection, Science, Latham & Watkins, Ropes & Gray, No, Growth, Forbes, Pharmaceutical industry

Galderma, the worlds largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products.

Key Points: 
  • Galderma, the worlds largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products.
  • ALASTINs premium skincare portfolio is fully incremental to and synergistic with Galdermas integrated dermatology platform.
  • Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically-proven products for daily skincare regimens and peri-procedural use.
  • Founded in 2015, ALASTIN Skincare, Inc. provides a comprehensive collection of cutting-edge products for daily skincare regimens and peri-procedural use.